BUZZ-肺病药物试验受挫，瑞银下调Regeneron PT评级

路透中文

Jun 05, 2025

BUZZ-肺病药物试验受挫，<a href="https://laohu8.com/S/UBS">瑞银</a>下调Regeneron PT评级

6月5日 - ** 券商瑞银集团（UBS）将药品制造商再生元制药公司REGN.O的预测价格从633美元下调至560美元。

** 瑞银称，"鉴于监管的不确定性和潜在竞争对手的加入"，已将吸烟者肺部药物伊替匹单抗从 "当前的合作管道 "中剔除。

** 公司与合作伙伴赛诺菲SASY.PA上周在 (link) 上表示，他们的实验性药物伊替匹单抗在一项针对俗称 "烟民肺 "的肺部疾病的后期试验中失败了，但在另一项针对同一疾病的试验中达到了目标

** 瑞银称，由于整合 23andMe 和增加肥胖症治疗的研发费用，REGN 将在近期到中期内增加 (link) 的运营费用。

** 不过，瑞银预计这些成本将在 2030 年后下降

** Eylea专营权疲软仍是我们近期REGN论断的主要障碍"--瑞银

** 包括本交易日的走势在内，REGN 今年累计下跌 31.8%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2541207487"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541207487\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541207487?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-05 23:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541207487","market":"us","top_or_hot":-1,"title":"BUZZ-肺病药物试验受挫，瑞银下调Regeneron PT评级","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-肺病药物试验受挫，<a href=\"https://laohu8.com/S/UBS\">瑞银</a>下调Regeneron PT评级</title></head><body><p>\n<span>6月5日</span><span> - </span>** 券商瑞银集团（UBS）将药品制造商<a href=\"https://laohu8.com/S/REGN\">再生元制药公司</a><span>REGN.O</span>的预测价格从633美元下调至560美元。 </p><p> ** 瑞银称，\"鉴于监管的不确定性和潜在竞争对手的加入\"，已将吸烟者肺部药物伊替匹单抗从 \"当前的合作管道 \"中剔除。</p><p>** 公司与合作伙伴<a href=\"https://laohu8.com/S/0O59.UK\">赛诺菲</a><span>SASY.PA</span>上周在 (<span>link</span>) 上表示，他们的实验性药物伊替匹单抗在一项<span> 针对</span>俗称 \"烟民肺 \"的肺部疾病的后期试验中失败了，但在另一项<span> 针对同一疾病的</span>试验中达到了目标</p><p>** 瑞银称，由于整合 23andMe 和增加肥胖症治疗的研发费用，REGN 将在近期到中期内增加 (<span>link</span>) 的运营费用。</p><p> ** 不过，瑞银预计这些成本将在 2030 年后下降 </p><p> ** Eylea专营权疲软仍是我们近期REGN论断的主要障碍\"--瑞银</p><p> ** 包括本交易日的走势在内，REGN 今年累计下跌 31.8% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-肺病药物试验受挫，瑞银下调Regeneron PT评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-肺病药物试验受挫，瑞银下调Regeneron PT评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-06-05 23:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-肺病药物试验受挫，<a href=\"https://laohu8.com/S/UBS\">瑞银</a>下调Regeneron PT评级</title></head><body><p>\n<span>6月5日</span><span> - </span>** 券商瑞银集团（UBS）将药品制造商<a href=\"https://laohu8.com/S/REGN\">再生元制药公司</a><span>REGN.O</span>的预测价格从633美元下调至560美元。 </p><p> ** 瑞银称，\"鉴于监管的不确定性和潜在竞争对手的加入\"，已将吸烟者肺部药物伊替匹单抗从 \"当前的合作管道 \"中剔除。</p><p>** 公司与合作伙伴<a href=\"https://laohu8.com/S/0O59.UK\">赛诺菲</a><span>SASY.PA</span>上周在 (<span>link</span>) 上表示，他们的实验性药物伊替匹单抗在一项<span> 针对</span>俗称 \"烟民肺 \"的肺部疾病的后期试验中失败了，但在另一项<span> 针对同一疾病的</span>试验中达到了目标</p><p>** 瑞银称，由于整合 23andMe 和增加肥胖症治疗的研发费用，REGN 将在近期到中期内增加 (<span>link</span>) 的运营费用。</p><p> ** 不过，瑞银预计这些成本将在 2030 年后下降 </p><p> ** Eylea专营权疲软仍是我们近期REGN论断的主要障碍\"--瑞银</p><p> ** 包括本交易日的走势在内，REGN 今年累计下跌 31.8% </p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL3S3S8146:1","article_id":"2541207487","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541207487","pubTimestamp":1749137819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"** 公司与合作伙伴赛诺菲SASY.PA上周在  上表示，他们的实验性药物伊替匹单抗在一项 针对俗称 \"烟民肺 \"的肺部疾病的后期试验中失败了，但在另一项 针对同一疾病的试验中达到了目标** 瑞银称，由于整合 23andMe 和增加肥胖症治疗的研发费用，REGN 将在近期到中期内增加  的运营费用。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"BUZZ-UBS downgrades Regeneron PT amid setback in lung disease drug trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"BUZZ-肺病药物试验受挫，瑞银下调Regeneron PT评级\n6月5日 - ** 券商瑞银集团（UBS）将药品制造商再生元制药公司REGN.O的预测价格从633美元下调至560美元。  ** 瑞银称，\"鉴于监管的不确定性和潜在竞争对手的加入\"，已将吸烟者肺部药物伊替匹单抗从 \"当前的合作管道 \"中剔除。** 公司与合作伙伴赛诺菲SASY.PA上周在 (link) 上表示，他们的实验性药物伊替匹单抗在一项 针对俗称 \"烟民肺 \"的肺部疾病的后期试验中失败了，但在另一项 针对同一疾病的试验中达到了目标** 瑞银称，由于整合 23andMe 和增加肥胖症治疗的研发费用，REGN 将在近期到中期内增加 (link) 的运营费用。 ** 不过，瑞银预计这些成本将在 2030 年后下降  ** Eylea专营权疲软仍是我们近期REGN论断的主要障碍\"--瑞银 ** 包括本交易日的走势在内，REGN 今年累计下跌 31.8% (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}